NKX101
Asset
Engineered natural killer cells recognize NKG2D ligands on malignant cells and kill them.
- Stage
- Phase 1
- Modality
- Cell therapy
- Target
- Not known
- 4
- Indications
- 2,332
- Trials
- 1
- Developer
Indications
4Adult aml
Phase 1, Active not recruiting, NCT04623944, clinicaltrials.gov, 14 Oct 2026
Mds
Phase 1, Active not recruiting, NCT04623944, clinicaltrials.gov, 14 Oct 2026
Refractory myelodysplastic syndrome
Phase 1, Active not recruiting, NCT04623944, clinicaltrials.gov, 14 Oct 2026
1 more
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials2,332
- Evidence for its targets2
- Competitors2
- Signals3
Every asset’s record: target, stage, trials and the evidence behind it.